The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

1. Gilead Sciences said it is voluntarily withdrawing its bladder cancer drug, sacituzumab govitecan (Trodelvy), after a confirmatory trial in patients with metastatic urothelial cancer failed to ...

Opens in a new tab or window The indication for sacituzumab govitecan (Trodelvy) in previously treated patients with locally advanced or metastatic urothelial cancer was withdrawn last month after ...

Opens in a new tab or window Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences announced on Friday. The decision was made ...

announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally advanced or metastatic urothelial cancer who ...

Gilead Sciences plans to voluntarily withdraw U.S. accelerated approval for Trodelvy in metastatic urothelial cancer ... approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients ...

Gilead has voluntarily withdrawn the US indication of sacituzumab govitecan-hziy (Trodelvy) for adult patients with locally advanced or metastatic urothelial cancer who have previously received a ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

the most common form of bladder cancer. The results of the TROPiCS-04 study compared Trodelvy (sacituzumab govitecan) to chemotherapy as second-line treatment for patients with locally advanced or ...

The accelerated approval of sacituzumab govitecan-hziy (Trodelvy) is being voluntarily withdrawn from the US market for the treatment of patients with locally advanced or metastatic urothelial cancer ...